Cargando…
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may compromise vaccine effectiveness and the ability of antibodies triggered by previous infection to protect against re-infection (1). Here we investigated whether Omicron escapes antibody neutralization in South Af...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855/ https://www.ncbi.nlm.nih.gov/pubmed/34909788 http://dx.doi.org/10.1101/2021.12.08.21267417 |
_version_ | 1784614862704345088 |
---|---|
author | Cele, Sandile Jackson, Laurelle Khoury, David S. Khan, Khadija Moyo-Gwete, Thandeka Tegally, Houriiyah San, James Emmanuel Cromer, Deborah Scheepers, Cathrine Amoako, Daniel Karim, Farina Bernstein, Mallory Lustig, Gila Archary, Derseree Smith, Muneerah Ganga, Yashica Jule, Zesuliwe Reedoy, Kajal Hwa, Shi-Hsia Giandhari, Jennifer Blackburn, Jonathan M. Gosnell, Bernadett I. Abdool Karim, Salim S. Hanekom, Willem von Gottberg, Anne Bhiman, Jinal Lessells, Richard J. Moosa, Mahomed-Yunus S. Davenport, Miles P. de Oliveira, Tulio Moore, Penny L. Sigal, Alex |
author_facet | Cele, Sandile Jackson, Laurelle Khoury, David S. Khan, Khadija Moyo-Gwete, Thandeka Tegally, Houriiyah San, James Emmanuel Cromer, Deborah Scheepers, Cathrine Amoako, Daniel Karim, Farina Bernstein, Mallory Lustig, Gila Archary, Derseree Smith, Muneerah Ganga, Yashica Jule, Zesuliwe Reedoy, Kajal Hwa, Shi-Hsia Giandhari, Jennifer Blackburn, Jonathan M. Gosnell, Bernadett I. Abdool Karim, Salim S. Hanekom, Willem von Gottberg, Anne Bhiman, Jinal Lessells, Richard J. Moosa, Mahomed-Yunus S. Davenport, Miles P. de Oliveira, Tulio Moore, Penny L. Sigal, Alex |
author_sort | Cele, Sandile |
collection | PubMed |
description | The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may compromise vaccine effectiveness and the ability of antibodies triggered by previous infection to protect against re-infection (1). Here we investigated whether Omicron escapes antibody neutralization in South Africans, either previously SARS-CoV-2 infected or uninfected, who were vaccinated with Pfizer BNT162b2. We also investigated if Omicron requires the ACE2 receptor to infect cells. We isolated and sequence confirmed live Omicron virus from an infected person in South Africa and compared plasma neutralization of this virus relative to an ancestral SARS-CoV-2 strain with the D614G mutation, observing that Omicron still required ACE2 to infect. For neutralization, blood samples were taken soon after vaccination, so that vaccine elicited neutralization was close to peak. Neutralization capacity of the D614G virus was much higher in infected and vaccinated versus vaccinated only participants but both groups had 22-fold Omicron escape from vaccine elicited neutralization. Previously infected and vaccinated individuals had residual neutralization predicted to confer 73% protection from symptomatic Omicron infection, while those without previous infection were predicted to retain only about 35%. Both groups were predicted to have substantial protection from severe disease. These data support the notion that high neutralization capacity elicited by a combination of infection and vaccination, and possibly boosting, could maintain reasonable effectiveness against Omicron. A waning neutralization response is likely to decrease vaccine effectiveness below these estimates. However, since protection from severe disease requires lower neutralization levels and involves T cell immunity, such protection may be maintained. |
format | Online Article Text |
id | pubmed-8669855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-86698552021-12-15 SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection Cele, Sandile Jackson, Laurelle Khoury, David S. Khan, Khadija Moyo-Gwete, Thandeka Tegally, Houriiyah San, James Emmanuel Cromer, Deborah Scheepers, Cathrine Amoako, Daniel Karim, Farina Bernstein, Mallory Lustig, Gila Archary, Derseree Smith, Muneerah Ganga, Yashica Jule, Zesuliwe Reedoy, Kajal Hwa, Shi-Hsia Giandhari, Jennifer Blackburn, Jonathan M. Gosnell, Bernadett I. Abdool Karim, Salim S. Hanekom, Willem von Gottberg, Anne Bhiman, Jinal Lessells, Richard J. Moosa, Mahomed-Yunus S. Davenport, Miles P. de Oliveira, Tulio Moore, Penny L. Sigal, Alex medRxiv Article The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may compromise vaccine effectiveness and the ability of antibodies triggered by previous infection to protect against re-infection (1). Here we investigated whether Omicron escapes antibody neutralization in South Africans, either previously SARS-CoV-2 infected or uninfected, who were vaccinated with Pfizer BNT162b2. We also investigated if Omicron requires the ACE2 receptor to infect cells. We isolated and sequence confirmed live Omicron virus from an infected person in South Africa and compared plasma neutralization of this virus relative to an ancestral SARS-CoV-2 strain with the D614G mutation, observing that Omicron still required ACE2 to infect. For neutralization, blood samples were taken soon after vaccination, so that vaccine elicited neutralization was close to peak. Neutralization capacity of the D614G virus was much higher in infected and vaccinated versus vaccinated only participants but both groups had 22-fold Omicron escape from vaccine elicited neutralization. Previously infected and vaccinated individuals had residual neutralization predicted to confer 73% protection from symptomatic Omicron infection, while those without previous infection were predicted to retain only about 35%. Both groups were predicted to have substantial protection from severe disease. These data support the notion that high neutralization capacity elicited by a combination of infection and vaccination, and possibly boosting, could maintain reasonable effectiveness against Omicron. A waning neutralization response is likely to decrease vaccine effectiveness below these estimates. However, since protection from severe disease requires lower neutralization levels and involves T cell immunity, such protection may be maintained. Cold Spring Harbor Laboratory 2021-12-17 /pmc/articles/PMC8669855/ /pubmed/34909788 http://dx.doi.org/10.1101/2021.12.08.21267417 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Cele, Sandile Jackson, Laurelle Khoury, David S. Khan, Khadija Moyo-Gwete, Thandeka Tegally, Houriiyah San, James Emmanuel Cromer, Deborah Scheepers, Cathrine Amoako, Daniel Karim, Farina Bernstein, Mallory Lustig, Gila Archary, Derseree Smith, Muneerah Ganga, Yashica Jule, Zesuliwe Reedoy, Kajal Hwa, Shi-Hsia Giandhari, Jennifer Blackburn, Jonathan M. Gosnell, Bernadett I. Abdool Karim, Salim S. Hanekom, Willem von Gottberg, Anne Bhiman, Jinal Lessells, Richard J. Moosa, Mahomed-Yunus S. Davenport, Miles P. de Oliveira, Tulio Moore, Penny L. Sigal, Alex SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection |
title | SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection |
title_full | SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection |
title_fullStr | SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection |
title_full_unstemmed | SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection |
title_short | SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection |
title_sort | sars-cov-2 omicron has extensive but incomplete escape of pfizer bnt162b2 elicited neutralization and requires ace2 for infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855/ https://www.ncbi.nlm.nih.gov/pubmed/34909788 http://dx.doi.org/10.1101/2021.12.08.21267417 |
work_keys_str_mv | AT celesandile sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT jacksonlaurelle sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT khourydavids sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT khankhadija sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT moyogwetethandeka sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT tegallyhouriiyah sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT sanjamesemmanuel sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT cromerdeborah sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT scheeperscathrine sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT amoakodaniel sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT karimfarina sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT bernsteinmallory sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT lustiggila sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT archaryderseree sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT smithmuneerah sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT gangayashica sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT julezesuliwe sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT reedoykajal sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT hwashihsia sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT giandharijennifer sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT blackburnjonathanm sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT gosnellbernadetti sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT abdoolkarimsalims sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT hanekomwillem sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT vongottberganne sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT bhimanjinal sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT lessellsrichardj sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT moosamahomedyunuss sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT davenportmilesp sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT deoliveiratulio sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT moorepennyl sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection AT sigalalex sarscov2omicronhasextensivebutincompleteescapeofpfizerbnt162b2elicitedneutralizationandrequiresace2forinfection |